JP7791119B2 - アルカフタジンとコルチコステロイドの組み合わせ - Google Patents

アルカフタジンとコルチコステロイドの組み合わせ

Info

Publication number
JP7791119B2
JP7791119B2 JP2022577618A JP2022577618A JP7791119B2 JP 7791119 B2 JP7791119 B2 JP 7791119B2 JP 2022577618 A JP2022577618 A JP 2022577618A JP 2022577618 A JP2022577618 A JP 2022577618A JP 7791119 B2 JP7791119 B2 JP 7791119B2
Authority
JP
Japan
Prior art keywords
composition
alcaftadine
fluticasone
topical
corticosteroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022577618A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530166A (ja
JP2023530166A5 (https=
Inventor
ウルハス・ドゥパッド
アキレシュ・シャルマ
ババサヘブ・アワレ
ヴィラージュ・シャー
アモル・アイワレ
Original Assignee
アルケム・ラボラトリーズ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルケム・ラボラトリーズ・リミテッド filed Critical アルケム・ラボラトリーズ・リミテッド
Publication of JP2023530166A publication Critical patent/JP2023530166A/ja
Publication of JP2023530166A5 publication Critical patent/JP2023530166A5/ja
Application granted granted Critical
Publication of JP7791119B2 publication Critical patent/JP7791119B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2022577618A 2020-06-15 2021-06-14 アルカフタジンとコルチコステロイドの組み合わせ Active JP7791119B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201921053286 2020-06-15
IN201921053286 2020-06-15
PCT/IB2021/055222 WO2021255622A1 (en) 2020-06-15 2021-06-14 Combination of alcaftadine and a corticosteroid

Publications (3)

Publication Number Publication Date
JP2023530166A JP2023530166A (ja) 2023-07-13
JP2023530166A5 JP2023530166A5 (https=) 2024-06-06
JP7791119B2 true JP7791119B2 (ja) 2025-12-23

Family

ID=76523259

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022577618A Active JP7791119B2 (ja) 2020-06-15 2021-06-14 アルカフタジンとコルチコステロイドの組み合わせ

Country Status (12)

Country Link
US (1) US20230218630A1 (https=)
EP (1) EP4164614A1 (https=)
JP (1) JP7791119B2 (https=)
KR (1) KR20230024928A (https=)
CN (1) CN115701988A (https=)
AU (1) AU2021291684A1 (https=)
BR (1) BR112022024840A2 (https=)
CA (1) CA3181959A1 (https=)
CL (1) CL2022003534A1 (https=)
MX (1) MX2022015965A (https=)
WO (1) WO2021255622A1 (https=)
ZA (1) ZA202212128B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
JP7606530B2 (ja) 2020-03-24 2024-12-25 シラノ セラピューティクス， インコーポレイテッド コロナウイルス感染症による化学感覚機能障害の治療
US20240173331A1 (en) 2021-04-01 2024-05-30 Alkem Laboratories Limited Nasal compositions comprising alcaftadine
CA3246013A1 (en) * 2022-01-06 2023-07-13 Cyrano Therapeutics, Inc. IMPROVED NASAL ADMINISTRATION OF PHARMACEUTICAL FORMULATIONS
WO2024228988A2 (en) * 2023-05-02 2024-11-07 Cyrano Therapeutics, Inc. Treatment for taste and smell loss
GR1010821B (el) * 2023-11-09 2024-11-15 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Σταθερο ομογενοποιημενο φαρμακευτικο ρινικο εναιωρημα συνδυασμου αζελαστινης και φλουτικαζονης

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003510275A (ja) 1999-09-30 2003-03-18 フィアトリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ロテプレドノールと抗ヒスタミン薬の新規な組み合わせ物
JP2005511724A (ja) 2001-12-05 2005-04-28 アルコン，インコーポレイテッド 鼻炎を処置するためのｈ１アンタゴニストおよび安全なステロイドの使用
JP2009507009A (ja) 2005-09-01 2009-02-19 バイオリポックス エービー 抗ヒスタミン剤及びコルチコステロイド含有リポソーム組成物と鼻炎及びその関連疾患を治療するための医薬の製造のためのその使用
JP2009533333A (ja) 2006-03-31 2009-09-17 ビスタコン・フアーマシユーチカルズ・エルエルシー 眼アレルギーの処置
JP2013522312A (ja) 2010-03-15 2013-06-13 アーシエックス セラピューティックス， インコーポレイテッド セチリジンの眼用製剤、および使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3877904D1 (de) 1987-11-13 1993-03-11 Asta Pharma Ag Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge.
IL101850A (en) 1991-06-13 1996-01-31 Janssen Pharmaceutica Nv 11-(4-Piperidinyl)-imidazo (2,1-b) (3) benzazepine derivatives their preparation and pharmaceutical compositions containing them
WO2011141929A2 (en) * 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
CN102283849A (zh) * 2011-06-29 2011-12-21 北京阜康仁生物制药科技有限公司 一种含有阿卡他定的药物组合物
RU2652352C2 (ru) * 2012-12-17 2018-04-25 Глаксо Груп Лимитед Комбинация левокабастина и флутиказона фуроата для лечения воспалительных и/или аллергических состояний
MX367674B (es) * 2013-09-13 2019-08-30 Glenmark Specialty Sa Composición farmacéutica de dosis fija estable que comprende mometasona y olopatadina.
WO2019022225A1 (ja) 2017-07-28 2019-01-31 参天製薬株式会社 アルカフタジン又はその塩を含有する水性医薬組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003510275A (ja) 1999-09-30 2003-03-18 フィアトリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ロテプレドノールと抗ヒスタミン薬の新規な組み合わせ物
JP2005511724A (ja) 2001-12-05 2005-04-28 アルコン，インコーポレイテッド 鼻炎を処置するためのｈ１アンタゴニストおよび安全なステロイドの使用
JP2009507009A (ja) 2005-09-01 2009-02-19 バイオリポックス エービー 抗ヒスタミン剤及びコルチコステロイド含有リポソーム組成物と鼻炎及びその関連疾患を治療するための医薬の製造のためのその使用
JP2009533333A (ja) 2006-03-31 2009-09-17 ビスタコン・フアーマシユーチカルズ・エルエルシー 眼アレルギーの処置
JP2013522312A (ja) 2010-03-15 2013-06-13 アーシエックス セラピューティックス， インコーポレイテッド セチリジンの眼用製剤、および使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Investigative Ophthalmology &Visual Science，2011年，Vol.52，Abstract No.6426

Also Published As

Publication number Publication date
CN115701988A (zh) 2023-02-14
ZA202212128B (en) 2024-04-24
MX2022015965A (es) 2023-03-14
AU2021291684A1 (en) 2022-12-08
JP2023530166A (ja) 2023-07-13
CA3181959A1 (en) 2021-12-23
US20230218630A1 (en) 2023-07-13
KR20230024928A (ko) 2023-02-21
EP4164614A1 (en) 2023-04-19
WO2021255622A1 (en) 2021-12-23
CL2022003534A1 (es) 2023-06-23
BR112022024840A2 (pt) 2022-12-27

Similar Documents

Publication Publication Date Title
JP7791119B2 (ja) アルカフタジンとコルチコステロイドの組み合わせ
EP2522365B1 (en) Compositions comprising azelastine and methods of use thereof
RU2568882C2 (ru) Фармацевтические композиции
JP5683719B2 (ja) ベポタスチン組成物
US12274702B2 (en) Nasal compositions comprising alcaftadine
US20120022032A1 (en) Corticosteroid compositions and methods of treatments thereof
AU2017276321A1 (en) Pharmaceutical composition comprising arformoterol and fluticasone furoate
US20150080355A1 (en) Pharmaceutical Compositions Comprising Ebastine and Fluticasone
RU2854644C1 (ru) Композиции для интраназального применения, содержащие алкафтадин
NZ620005B2 (en) Pharmaceutical composition comprising ebastine and fluticasone
NZ707754A (en) Combination of glycopyrrolate and a beta2 -agonist

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240529

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250909

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251211

R150 Certificate of patent or registration of utility model

Ref document number: 7791119

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150